Clinical and biological markers of asthma control

Expert Review of Clinical Immunology

Volumn 10, Issue 11, 2014, Pages 1453-1461

  Tartibi, Hana M ^a   Bahna, Sami L ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

asthma control; Asthma Control Questionnaire; Asthma Control Test; asthma evaluation; asthma markers; eosinophil cationic protein; exhaled nitric oxide; GINA; JTFPP; NAEPP; serum periostin; sputum eosinophils; urinary leukotriene E4

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; EOSINOPHIL CATIONIC PROTEIN; LEUKOTRIENE E4; NITRIC OXIDE; TRANSCRIPTION FACTOR RUNX2; VOLATILE ORGANIC COMPOUND;

ASTHMA; ASTHMA CONTROL; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA CONTROL SCORING SYSTEM; ASTHMA CONTROL TEST; ASTHMA THERAPY ASSESSMENT QUESTIONNAIRE; CLINICAL PRACTICE; DISEASE CONTROL; DISEASE EXACERBATION; EOSINOPHIL; EOSINOPHIL COUNT; EXPIRED AIR; FORCED EXPIRATORY VOLUME; HEALTH EDUCATION; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; RESPIRATORY TRACT INFLAMMATION; REVIEW; SCORING SYSTEM; SELF CONCEPT; SPIROMETRY; SPUTUM; TH2 CELL; METABOLISM;

ASTHMA; BIOLOGICAL MARKERS; HUMANS;

EID: 84911476894     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.962516     Document Type: Review

References (78)

1. Sembajwe G, Cifuentes M, Tak SW, et al. National income, self-reported wheezing and asthma diagnosis from the World Health Survey. Eur Respir J 2010;35:279-86
2. Asthma surveillance data. Centers of Disease Control and Prevention. Atlanta, GA: CDC, 2014. Available from: www.cdc.gov/asthma/asthmadata.htm [Last accessed 20 July 2014] • Detailed US national data on asthma prevalence, impact on life, healthcare and cost.
3. National Asthma Education and Prevention Program Expert Panel Report: 3. Guidelines for the diagnosis and management of asthma. Bethesda, MD: national Heart Lung and Blood Institute; 2007. Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf [Last accessed 15 June 2014].
4. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7
5. Juniper EF, Svensson K, Mörk AC, Sta°hl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99: 553-8
6. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-21
7. Jia CE, Zhang HP, Lv Y, et al. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: systematic review and meta-analysis. J Allergy Clin Immunol 2013;131:695-703
8. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65
9. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124:719-23
10. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117:549-56
11. Schatz M, Mosen DM, Kosinski M, et al. Validity of the Asthma Control Test completed at home. Am J Manag Care 2007;13:661-7
12. Schatz M, Zeiger R, Drane A, et al. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J Allergy Clin Immunol 2007;119:336-43
13. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007;119:817-25
14. Barrett A, Clark M, Demuro C, Esser D. Proxy-reported questionnaires for young children with asthma: a structured review. Eur Respir J 2013;42:513-26
15. Vollmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999;160:1647-52
16. Reddel HK, Taylor DR, Bateman ED, et al. American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
17. Rapino D, Attanasi M, Consilvio NP, et al. Evaluation of association between airway hyperresponsiveness, asthma control test, and asthma therapy assessment questionnaire in asthmatic children. Multidiscip Respir Med 2013;8:48
18. Boulet L-P, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest 2002;122:2217-23.
19. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology and Joint Council of Allergy, Asthma and Immunology. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005;116:S3-11.
20. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2012Available from: www. ginasthma.org [Last accessed 20 June 2014].
21. Olaguibel JM, Quirce S, Juliá B, et al. MAGIC Study Group. Measurement of asthma control according to Global Initiative for Asthma guidelines: a comparison with the Asthma Control Questionnaire. Respir Res 2012;13:50
22. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78: 915-18
23. Paraskakis E, Brindicci C, Fleming L, et al. Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. Am J Respir Crit Care Med 2006;174:260-7
24. Szefler SJ. Advances in pediatric asthma in 2013: coordinating asthma care. J Allergy Clin Immunol 2014;133:654-61
25. Payne DN, Adcock IM, Wilson NM, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001;164:1376-81
26. Lim S, Jatakanon A, Meah S, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax 2000;55:184-8
27. Warke TJ, Fitch PS, Brown V, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax 2002;57:383-7
28. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30
29. Khalili B, Boggs PB, Bahna SL. Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy 2007;62:1171-4
30. Borrill Z, Clough D, Truman N, et al. A comparison of exhaled nitric oxide measurements performed using three different analysers. Respir Med 2006;100: 1392-6
31. Taylor DR, Mandhane P, Greene JM, et al. Factors affecting exhaled nitric oxide measurements: the effect of sex. Respir Res 2007;8:82
32. Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest 2008;133:1232-42
33. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15
34. Bahna SL. Should exhaled nitric oxide measurement be part of routine asthma management? Ann Allergy Asthma Immunol 2012;109:289-91
35. Fritsch M, Uxa S, Horak F Jr, et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. Pediatr Pulmonol 2006;41:855-62
36. Gelb AF, Flynn Taylor C, Shinar CM, et al. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006;129:1492-6
37. Khalili B, Boggs PB, Shi R, Bahna SL. Discrepancy between clinical asthma control assessment tools and fractional exhaled nitric oxide. Ann Allergy Asthma Immunol 2008;101:124-9
38. Vijverberg SJH, Koster ES, Koenderman L, et al. Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. Pediatr Allergy Immunol 2012;23: 529-36
39. Ferrer M, Jarque A, Tosca R, Michavila A. Is it necessary to treat all asthmatic children with raised levels of exhaled nitric oxide?: treating the patient or the data. Allergol Immunopathol (Madr) 2011;39:280-3
40. Yavuz ST, Civelek E, Sahiner UM, et al. Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement. Ann Allergy Asthma Immunol 2012;109:36-40
41. Petsky HL, Cates CJ, Li A, et al. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009;4:CD006340
42. Fahy JV, Boushey HA, Lazarus SC, et al. NHLBI Asthma Clinical Research Network. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med 2001;163:1470-5
43. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62: 1043-9
44. Vijverberg SJ, Hilvering B, Raaijmakers JA, et al. Clinical utility of asthma biomarkers: from bench to bedside. Biologics 2013;7: 199-210
45. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J 2002;20:1s-52s
46. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129:S9-23
47. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24
48. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208
49. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002;57:178-82
50. Horváth I, Hunt J, Barnes PJ, et al. ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26: 523-48
51. Leung TF, Ko FW, Wong GW. Recent advances in asthma biomarker research. Ther Adv Respir Dis 2013;7:297-308
52. Fens N, de Nijs SB, Peters S, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J 2011;38:1301-9
53. Bofan M, Mores N, Baron M, et al. Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. J Breath Res 2013;7:017103
54. van der Schee MP, Palmay R, Cowan JO, Taylor DR. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy 2013;43: 1217-25
55. Ibrahim B, Basanta M, Cadden P, et al. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax 2011;66:804-9
56. Dallinga JW, Robroeks CM, van Berkel JJ, et al. Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy 2010;40:68-76
57. Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009;180: 1076-82
58. Dragonieri S, Schot R, Mertens BJ, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007;120:856-62
59. Koh GC, Shek LP, Goh DY, et al. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med 2007;101:696-705
60. Bystrom J, Amin K, Bishop-Bailey D. Analysing the eosinophil cationic protein-a clue to the function of the eosinophil granulocyte. Respir Res 2011;12:10
61. Malinovschi A, Fonseca JA, Jacinto T, et al. Exhaled nitric oxide and blood eosinophils independently associate with wheeze and asthma events in NHANES subjects. J Allergy Clin Immunol 2013;132:821-7
62. Kim MA, Shin YS, Pham le D, Park HS. Adult asthma biomarkers. Curr Opin Allergy Clin Immunol 2014;14:49-54
63. Jia G, Erickson RW, Choy DF, et al. Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130: 647-654.e10
64. Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305-12.e3
65. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98
66. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-11
67. Fujita M, Ueki S, Ito W, et al. C-reactive protein levels in the serum of asthmatic patients. Ann Allergy Asthma Immunol 2007;99:48-53
68. Qian FH, Zhang Q, Zhou LF, et al. High-sensitivity C-reactive protein: a predicative marker in severe asthma. Respirology 2008;13:664-9
69. Allam MH, Said AF, El Samie Omran AA, et al. High sensitivity C-reactive protein: its correlation with sputum cell counts in bronchial asthma. Respir Med 2009;103: 1878-84
70. Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, et al. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma. Respir Med 2009;103:379-85
71. Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J 2006;27:908-12
72. Deraz TE, Kamel TB, El-Kerdany TA, El-Ghazoly HM. High-sensitivity C reactive protein as a biomarker for grading of childhood asthma in relation to clinical classification, induced sputum cellularity, and spirometry. Pediatr Pulmonol 2012;4s7: 220-5
73. Ramirez D, Patel P, Casillas A, et al. Assessment of high-sensitivity C-reactive protein as a marker of airway inflammation in asthma. Ann Allergy Asthma Immunol 2010;104:485-9
74. Kato G, Takahashi K, Izuhara K, et al. Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study. Biomark Insights 2013;8:97-105
75. Duffield-Lillico AJ, Boyle JO, Zhou XK, et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) 2009;2:322-9
76. Abd El-Motaleb GS, Abou Amer AA, Elawa GM, Abo Alsood Abd Elfattah M. Study of urinary leukotriene E4 levels in children with acute asthma. Int J Gen Med 2014;7:131-5
77. Gill R, Krishnan S, Dozor AJ. Low-level environmental tobacco smoke exposure and inflammatory biomarkers in children with asthma. J Asthma 2014;51:355-9
78. Lang JE, Dozor AJ, Holbrook JT, et al. American Lung Association-Asthma Clinical Research Centers. Biologic mechanisms of environmental tobacco smoke in children with poorly controlled asthma: results from a multicenter clinical trial. J Allergy Clin Immunol Pract 2013;1:172-80